	US 11,938,159 B2
	Oncolytic adenoviruses armed with heterologous genes
Brian Robert Champion, Oxfordshire (GB); Alice Claire Noel Brown, Oxfordshire (GB); Kerry David Fisher, Oxfordshire (GB); and Tamara Nicolson, Oxfordshire (GB)
Assigned to AKAMIS BIO LIMITED, Abingdon (GB)
Filed by AKAMIS BIO LIMITED, Oxfordshire (GB)
Filed on Dec. 23, 2020, as Appl. No. 17/247,787.
Application 17/247,787 is a continuation of application No. 15/967,093, filed on Apr. 30, 2018, granted, now 11,439,678.
Application 15/967,093 is a continuation of application No. 15/031,716, granted, now 9,987,314, issued on Jun. 5, 2018, previously published as PCT/EP2014/072919, filed on Oct. 24, 2014.
Claims priority of application No. 1318880 (GB), filed on Oct. 25, 2013; application No. 1318885 (GB), filed on Oct. 25, 2013; application No. 1322851 (GB), filed on Dec. 23, 2013; application No. 1401159 (GB), filed on Jan. 23, 2014; and application No. 1406470 (GB), filed on Apr. 10, 2014.
Prior Publication US 2021/0187047 A1, Jun. 24, 2021
Int. Cl. A61K 35/761 (2015.01); A61K 39/00 (2006.01); C12N 7/00 (2006.01)

CPC A61K 35/761 (2013.01) [A61K 39/0011 (2013.01); C12N 7/00 (2013.01); A61K 2039/5256 (2013.01); C12N 2710/10332 (2013.01); C12N 2710/10343 (2013.01)]

10 Claims

1. A plasmid comprising a p15A bacterial origin of replication, a kanamycin resistance gene, and an Enadenotucirev genome sequence comprising an L5 gene and a DNA sequence comprising one or more unique restriction sites inserted in a region located at the 3′ end of the L5 gene, wherein the region comprises SEQ ID NO: 11 and the DNA sequence is comprised between nucleotides 12 and 13 in SEQ ID NO: 11 or between a place corresponding to nucleotides 29356 and 29357 in SEQ ID NO: 12.